These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 22231041)

  • 1. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Blumenfeld Z
    J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
    [No Abstract]   [Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.
    Tomao F; Benedetti Panici P; Tomao S
    J Clin Oncol; 2012 Sep; 30(26):3310-1; author reply 3312-3. PubMed ID: 22649128
    [No Abstract]   [Full Text] [Related]  

  • 4. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer.
    Saloustros E; Stratakis CA
    J Clin Oncol; 2012 Sep; 30(26):3311-2. PubMed ID: 22649148
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
    J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?
    Partridge AH
    J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046
    [No Abstract]   [Full Text] [Related]  

  • 9. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.
    Elgindy EA; El-Haieg DO; Khorshid OM; Ismail EI; Abdelgawad M; Sallam HN; Abou-Setta AM
    Obstet Gynecol; 2013 Jan; 121(1):78-86. PubMed ID: 23262931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
    Roché H; Kerbrat P; Bonneterre J; Fargeot P; Fumoleau P; Monnier A; Clavère P; Goudier MJ; Chollet P; Guastalla JP; Serin D
    Ann Oncol; 2006 Aug; 17(8):1221-7. PubMed ID: 16731539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide.
    Karimi-Zarchi M; Forat-Yazdi M; Vafaeenasab MR; Nakhaie-Moghadam M; Miratashi-Yazdi A; Teimoori S; Dehghani-Tafti A
    Eur J Gynaecol Oncol; 2014; 35(1):59-61. PubMed ID: 24654464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
    Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
    J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
    Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
    Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
    Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
    Arriagada R; Lê MG; Spielmann M; Mauriac L; Bonneterre J; Namer M; Delozier T; Hill C; Tursz T
    Ann Oncol; 2005 Mar; 16(3):389-96. PubMed ID: 15677625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
    Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.